** Sarepta Therapeutics SRPT.O said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S.-approved gene therapy for Duchenne muscular dystrophy.

DOCTORS COULD BECOME MORE CAUTIOUS

** Jefferies ("buy"; PT: $165) says the therapy Elevidys could perhaps receive a blackbox warning for fatal acute liver-failure as a precautionary measure

** Brokerage adds if the death becomes attributed to SRPT's therapy, adoption could become more skewed towards patients who can walk and a strong trend of use by patients who cannot would reassure the Street about safety fears

** H.C. Wainwright ("sell"; PT: $75) says since the liver failure and death occurred in an older patient who could not walk, doctors could become even more cautious on dosing these patients

** William Blair ("outperform") says the recent infection in patient could have exacerbated the condition, suggesting additional safety screening measures could be implemented in the future to prevent future deaths

** BMO Capital Markets ("outperform"; PT: $200) says while this unfortunately negatively impacts Elevidys' overall safety profile, the benefit/risk profile is acceptable given unmet need in the DMD space

(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))